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Abstract Objective: Genetic variants
in the NOD2/CARD15 gene resulting
in a diminished capacity to activate
NF-κB in response to bacterial cell
wall products have been associated
with Crohn’s disease (CD). Recently,
we found an association between
the variant Leu1007fsinsC of the
NOD2/CARD15 gene (SNP13) and
a significantly increased rate of trans-
plant related mortality (TRM) due
to intestinal and pulmonary compli-
cations in stem cell transplantation
(SCT). To assess a possible contribu-
tion of variants in the NOD2/CARD15
gene to sepsis related mortality (SRM)
we investigated 132 prospectively
characterised, consecutive patients
with sepsis. Design and patients: The
three most common NOD2/CARD15
variants (Arg702Trp, Gly908Arg,
and Leu1007fsinsC) were determined
in 132 prospectively characterised
patients with sepsis attended to three
intensive care units at the University
of Regensburg by Taqman PCR.
NOD2/CARD15 genotype and
major patients’ characteristics were
correlated with SRM. Results:
Patient groups with and without
NOD2/CARD15 variants did not
differ in their clinical characteris-
tics such as median age, gender,
reason for admission or APACHE
score; however, SRM (day 30) was
increased in patients with
NOD2/CARD15 coding variants
(42 vs. 31%) and was highest (57%)
in 8 patients carrying the
Leu1007fsinsC variant (p < 0.05).
Multivariate analysis demonstrated
the Leu1007fsinsC genetic variant
as an independent risk factor for
SRM. Conclusion: Our findings
indicate a major role of
NOD2/CARD15 coding variants
for SRM. This may be indicative
for a role of impaired barrier func-
tion and bacterial translocation in
the pathophysiology of early sepsis
related death.
Keywords Sepsis · NOD2/CARD15 ·
SNPs · Genetic risk factors
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Introduction
Sepsis is defined as the presence or presumed presence
of an infection accompanied by evidence of a systemic
response [1–3]. It is the most common cause of death
in non-coronary intensive care units [4]. The current
pathophysiological concepts of sepsis suggest a local
immune response followed by a systemic release of pro-
inflammatory and anti-inflammatory mediators, leading
to a systemic imbalance of inflammation, progressive
endothelial dysfunction, loss of blood pressure control,
deterioration of the coagulation system and ultimately
multiple organ dysfunctions [5–9].
Predisposing factors have been identified; among them
patient age, pre-existing chronic diseases and immuno-
suppressive medication influence a patient’s response to
infection [10]. In recent years the role of genetic factors
determining the susceptibility to sepsis and the severity
of the disease has been explored [11–16]. A number of
genetic polymorphisms have been identified influencing
the risk of infection and/or of mortality. Single nucleotide
polymorphisms (SNPs), as well as insertion and deletion
polymorphisms, can characterize an individual’s risk for
sepsis, organ dysfunction or death: A polymorphism in
the tumour necrosis factor (TNF)-α gene, the TNF-2
allele, has been associated with elevated serum levels
of TNF and an increased risk of mortality from septic
shock [13, 16, 17]. A SNP of the interleukin-1 receptor
antagonist (IL-1ra) gene (IL-1RN*2) has been associated
with reduced IL-1ra production and consecutive increased
mortality rates [18, 19]. Furthermore, polymorphisms
in Toll-like receptor (TLR) and interferon-γ genes also
influence the susceptibility to sepsis [14, 16, 20].
The intestine is a reservoir of bacteria and of bacterial
products (endotoxins, exotoxins and cell wall fragments)
that may escape from the intestinal lumen to the mesen-
teric lymph nodes and the bloodstream. The intestinal
mucosa is the major barrier against those bacteria and
toxins, protecting the body from the potentially harmful
pathogens. In sepsis the mucosal barrier is compromised
and micro-organisms and their toxic products can gain
access to the portal and systemic circulations with delete-
rious effects [21, 22]. After bacterial translocation across
the mucosal barrier, systemic inflammatory response syn-
drome (SIRS) and multiple organ dysfunction syndrome
(MODS) may develop leading to death of the patient [23].
Results of several clinical studies have demonstrated that
bacteria isolated from patients with systemic infections
are often the same strain as bacteria predominantly present
in the fecal flora [24].
The mucosal barrier is formed primarily mechanically
by the epithelial cell barrier and by intercellular junctions
as well as immunologically the combined innate and adap-
tive immune system. Alterations in one these components
of the intestinal barrier have been reported to be responsi-
ble for bacterial and toxin translocation. The cells of the
intestinal mucosa express a number of so-called pattern-
recognition receptors (PRRs) which detect microbial
components extra- or intra-cellularly [25, 26]. Mutations
in a PRR, the NOD2/CARD15 gene, coding for a CAspase
Recruitment Domain (CARD)-containing protein, were
found in up to 40% of patients with Crohn’s disease (CD),
a chronic inflammatory bowel disease (IBD) [27–29].
Several SNPs in the NOD2/CARD15 gene have been
identified, three of which have been shown to be indepen-
dently associated with CD (Arg702Trp, Gly908Arg, and
Leu1007fsinsC). Muramyl dipeptide (MDP), a component
of the bacterial wall derived from peptidoglycane, is
the ligand bound by NOD2 [30, 31]. The three major
NOD2/CARD15 SNPs, Arg702Trp, Gly908Arg and
Leu1007fsinsC, are all located within or near a leucine-
rich repeat (LRR) region of NOD2/CARD15 [32]. The
LRR domain is located at the C-terminus of the protein
and represents the major structural motif that functions
as a PRR for broad types of microbial components. In
addition to the three major-risk alleles, a number of
extremely rare amino acid polymorphisms, particularly
within or near the LRR domain of NOD2/CARD15, have
been defined.
Treatment of cells transfected with wild-type
NOD2/CARD15 with bacterial peptidoglycan induces
NF-κB activation. The frameshift variant, Leu1007fsinsC,
truncates the LRR domain and is associated with
a markedly reduced NF-κB activation [33, 34]. In com-
parison, the Arg702Trp and Gly908Arg variants respond
more to stimulation with bacterial wall products than the
Leu1007fsinsC variant; however, the ability to activate
NF-κB is still significantly reduced.
NOD2/CARD15 is a member of a superfamily of
genes, the NBS-LRR proteins (for nucleotide-binding
site and leucine-rich repeat), which are involved in
intracellular recognition of microbes and their prod-
ucts [35] and is expressed mainly in the Paneth cells
of the epithelium as well as intestinal macrophages and
dendritic cells. Mutations in NOD2/CARD15 also are
a risk factor for the development of graft-vs.-host disease
(GvHD) after allogeneic stem cell transplantation (SCT).
Recently, we showed that the incidence of severe GvHD
rose from 18% in donor/recipient pairs without any
NOD2 mutation to 37% in pairs with either donor or
recipient mutations with a subsequent increase of treat-
ment related mortality (TRM) from 33 to 60% [36–38].
When donor and recipient both had NOD2 mutations
severe GvHD rose from 22 to 55% and TRM from 38
to 100% [36–38]. A deficient antibacterial response in
Paneth cells of the recipient donor monocytes could
result in increased bacterial translocation [34, 39–41].
We could further demonstrate that TRM in patients
with Arg702Trp, Gly908Arg and Leu1007fsinsC mu-
tations was caused mainly by intestinal and pulmonary
complications, which were likely due to bacterial translo-
cation in these organs [38]. This led us to investigate
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the role of NOD2/CARD15 mutations in patients with
sepsis [42].
Material and methods
Patients
Approval for this study was obtained from the local in-
stitutional review board. All patients who were admitted
to the intensive care units of the University Hospital of
Regensburg between 2001 and April 2004 were evaluated
prospectively for their clinical data. One hundred thirty-
two patients were included in the study when they fulfilled
the criteria of sepsis. According to the Consensus Con-
ference Criteria [43], sepsis was diagnosed based on the
presence of at least three systemic inflammatory response
syndrome criteria with the simultaneous identification of
focal infection by clinical, radiological or microbiological
criteria. Microbiological cultures were done according to
standard techniques. Sepsis-related mortality was defined
as mortality within 30 days after study entry, as obtained
form hospital records. The Acute Physiology and Chronic
Health Evaluation (APACHE) [44–47] and the Simplified
Acute Physiology Score II (SAPS II) [48, 49] were used to
classify the severity of sepsis. The first blood sample was
drawn as soon as possible after patients fulfilled the criteria
of sepsis for the first time (day 1).
All DNA studies were carried out after the patients
were clinically characterized and had been entered into
the database.
Isolation of DNA
The DNA was isolated from buffy coats of EDTA blood
samples with DNeasy columns (Quiagen, Hilden, Ger-
many) according to the manufacturer’s protocol. The
DNA was precipitated by adding 100% isopropanol.
The supernatant was carefully removed, the pellet air-
dried and re-suspended in 50–200 µL sterile water. The
DNA-concentration was measured with 1:20 pre-diluted
genomic DNA at 260 and 280 nm wavelength. The iso-
lated genomic DNA was diluted to a final concentration of
20 ng/µL and stored at –20 °C.
Determination of NOD2 genotype
Single nucleotide polymorphisms Arg702Trp (SNP8),
Gly908Arg (SNP12) and Leu1007fsinsC (SNP13) were
determined by allele specific PCR (Taqman). A 10-µL re-
action mix for one SNP-typing consisted of 5 µL of 2xTaq-
Man Universal PCR Master Mix (Applied Biosystems),
1 µL of forward and reverse primer, 1 µL of wildtype- and
mutant probe and 20 ng genomic DNA.
All reactions were performed in 384-well plates (Ab-
gene, Epsom, UK) in an external thermocycler (Primus-
HT; MWG Biotech). The cycler conditions were: 50 °C for
2 min, 95 °C for 10 min, followed by 45 cycles of 95 °C for
15 s (melting) and 60 °C for 1 min (annealing/extension).
During the PCR the released fluorescence was measured
by the ABI PRISM 7700 Sequence Detection System (PE
Applied Biosystems, Forster City, Calif.)
Increases in the amount of reporter dye fluorescence
during the 45 cycles of amplification were analysed
using Sequence Detector software (SDS version 2.2, PE
Applied Biosystems). Changes in reporter dye fluores-
cence of 6-FAM vs. changes in reporter dye fluorescence
of TET were plotted (homozygous FAM vs. homozygous
TET vs. heterozygous FAM/TET). [For primer and PCR
probe (all synthesized by MWG Biotech, Ebersberg,
Germany) sequences see ESM].
A total of 117 DNA samples were additionally com-
pletely sequenced to confirm Taqman results and to detect
private mutations in the relevant exons. In the remaining
15 patients no complete sequence could be obtained. All
together, five private mutations were found. All of them
were silent mutations not associated with changes in the
amino acid sequence.
Statistics
Major patient characteristics, such as age, gender, cate-
gory of admission (surgical emergency/other), underlying
disease (malignant/haematological vs. others) as well as
the results of NOD2/CARD15 genotyping, were listed for
each patient. Haematological patients were regarded as
separate group due to their bad outcome [50]. Patient char-
acteristics, APACHE and SAPS scores at admission and in
the course of ICU treatment as well as outcome (survival
at day 30) were analysed in relation to NOD2/CARD15
mutations. Frequencies were compared by chi-square
analysis, and t-tests were used for parametric variables.
Survival was calculated using Kaplan–Meier statistics, and
groups were compared by log-rank tests. For multivariate
analysis of risk factors affecting survival and confounding
variables, such as age and gender, stepwise Cox regression
models were used (Table 1). The limit for reverse selection
process was 0.2. Statistical analysis was performed by the
help of the SPSS software (version 12.00).
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Table 1 Multivariate Cox regression analysis of 30-day survival. HR hazard ratio with 95% CI are shown. The following groups were
compared with regard to NOD2/CARD15 mutations: WT vs. SNP8 and 12 (Arg702Trp/Gly908Arg) vs. SNP 13 (Leu1007fsinsC)
Parameter Group Survival Significance HR 95% CI
(Kaplan–Meier, %) ( p)
Age (years) < 60 69 n.s. 1.16 0.5–2.5
> 60 61
Category of admission Other 69 n.s. 1.89 0.9–3.9
Surgical emergency 58
Underlying disease Non-haematological 72 n.s. 1.72 0.6–4.3
haematological/malignancy 64
NOD2/CARD15 Wildtype 68.9 n.s. 1.72 0.61.4–10.14.7
Mutation Arg702Trp/Gly908Arg 64.7/37.5 0.027 3.72 1.4–10.1
Leu1007fsinsC
Results
Patients’ characteristics of the groups with wildtype (WT)
and variant NOD2/CARD15 sequence did not differ
significantly (see Table 2). The median age of the 107
WT patients was 55 years (range 20–91 years) of the
17 Arg702Trp or Gly908Arg (Arg702Trp/Gly908Arg)
mutated patients 70 years (range 17–80 years) and of the 8
patients with Leu1007fsinsC 58 years (range 35–93 years).
Of the 17 patients of the Arg702Trp/Gly908Arg group,
only 2 had the Gly908Arg variant. No homozygous or
compound heterozygous patients with NOD2/CARD15
variants were among our patients.
The gender ratio (female/male) was WT: 33/74,
Arg702Trp/Gly908Arg: 2/15 and Leu1007fsinsC: 3/5.
Emergency surgery as the reason for admission occurred
in 33 (31%), 2 (12%) and 3 (38%) in the respective
groups. Malignancy as underlying disease was present in
19 (18%) of WT, 3 (18%) of Arg702Trp/Gly908Arg and 0
of Leu1007fsinsC patients. Previous surgery had been per-
formed in 48 (45%) WT, 5 (29%) Arg702Trp/Gly908Arg
and 2 (25%) Leu1007fsinsC patients.
Gram-positive bacteria were isolated from blood
samples in 29 (27%) WT patients, 5 (29%) Arg702Trp/
Gly908Arg patients and 4 (50%) Leu1007fsinsC in-
dividuals (see Table 2). The respective number for
Gram-negative bacteria were 25 (23%), 5 (29%) and 4
(50%). This indicates that in 50% of all patients without
Parameter WT patients Arg702Trp/Gly908Arg Leu1007fsinsC
APACHE score at admission 22.6 ± 6.9 20.5 ± 7.7 23.1 ± 5.3
SAPS score at admission 45.2 ± 15.3 43.9 ± 18 48.6 ± 9.4
FiO2 at admission 0.50 ± 0.19 0.47 ± 0.19 0.46 ± 0.20
pO2/FiO2 < 200 at admission (n) 70 (66) 11 (64) 6 (75)
APACHE score at week1 19.6 ± 7.1 20.0 ± 7.6 21.5 ± 11.4
SAPS score at week1 40.7 ± 17.8 42.0 ± 15.0 44.1 ± 18.0
FiO2 at week1 0.40 ± 0.14 0.45 ± 0.23 0.54 ± 0.31
( p < 0.001 vs. WT)
pO2/FiO2 < 200 week 1 (n) 41 (42) 7 (41) 5 (63)
Numbers in parentheses are percentages
Table 2 Characteristics of the
patient populations with respect
to disease severity. WT wildtype
NOD2/CARD15 variants, 58% of all individuals with
Arg702Trp or Gly908Arg variants (n.s. vs. WT) and 100%
of Leu1007fsinsC variant patients (p < 0.05 vs. WT,
z = 2.3, chi-square test), Gram-negative or Gram-positive
bacteria could be detected in blood cultures. Fungi, viruses
or mixed infections were found in 34 (32%) WT patients,
2 (12%) Arg702Trp/Gly908Arg patients and in none of
the Leu1007fsinsC patients.
As rated by the treating doctors the infectious
focus was likely to be pulmonary in 45 (42%) of
NOD2/CARD15 WT patients, 9 (53%) Arg702Trp/
Gly908Arg patients and 5 (63%) Leu1007fsinsC indi-
viduals (see Table 2). The respective numbers for the
gastrointestinal tract to be the most likely focus of sepsis
were 30 (28%), 1 (6%) and 2 (25%).
Whereas there were no differences in functional
parameters at admission, there were significant differ-
ences after 1 week (Table 2). At admission APACHE
scores were (mean ± SD) 22.6 ± 6.9 in WT, 20.5 ± 7.7 in
Arg702Trp/Gly908Arg and 23.1 ± 5.3 in Leu1007fsinsC
patients. The SAPS scores were 45.2 ± 15.3, 43.9 ± 18
and 48.6 ± 9.4, and FiO2 as a parameter of respiratory
function was 0.50 ± 0.19, 0.47 ± 0.19 and 0.46 ± 0.20,
respectively. After 1 week, APACHE scores were
19.6 ± 7.1 in WT, 20.0 ± 7.6 in Arg702Trp/Gly908Arg
and 21.5 ± 11.4 in Leu1007fsinsC patients ( p = 0.08).
The SAPS scores were 40.7 ± 17.8, 42.0 ± 15.0 and
44.1 ± 18.0, respectively (n.s.). FiO2 was 0.40 ± 0.14 in
1545
Fig. 1 Kaplan–Meier survival
plot of sepsis patients grouped
according to presence or absence
of NOD2/CARD15
Arg702Trp/Gly908Arg or
Leu1007fsinsC mutations.
Differences between groups
were compared by log-rank
analysis
WT, 0.45 ± 0.23 in Arg702Trp/Gly908Arg (p < 0.01 vs.
WT) and 0.54 ± 0.31 (p < 0.001 vs. WT).
Sepsis-related mortality after 18 days was 19%
in WT, 29% in Arg702Trp/Gly908Arg and 57% in
Leu1007fsinsC patients. After 31 days respective data
were 31, 36 and 57%. Kaplan–Meier survival plot of
sepsis patients grouped according to presence or ab-
sence of NOD2/CARD15 Arg702Trp/Gly908Arg or
Leu1007fsinsC mutations is given in Fig. 1. Differences
between groups were compared by log-rank analysis.
A significantly increased risk for SRM was evident in
patients with Leu1007fsinsC (p = 0.03).
Multivariate analysis clearly demonstrated Leu1007-
fsinsC to be an independent risk factor for early SRM
(Table 2; HR = 3.72, 95% CI = 1.4–10.1; p = 0.027).
Discussion
Our study is the first to report a strong impact of
a NOD2/CARD15 variant (Leu1007fsinsC) on sepsis-
related mortality (SRM) and the outcome of sepsis. The
frequency of NOD2/CARD15 variants among patients
with sepsis was not found to be increased compared with
healthy control populations as reported by others. Among
132 patients 25 individuals carrying NOD2/CARD15
variants were detected corresponding to 19% of the inves-
tigated cohort. The reported frequency of heterozygous
NOD2/CARD15 variants among healthy German patients
in a study on CD was 14% [29]. In an own study in a stem
cell transplantation setting NOD2/CARD15 mutations
occurred with a frequency of 21.8% in patients and 13.7%
in stem cell donors [36]. In the latter study only one
homozygous mutation was observed, whereas all other
patients and donors with mutations were heterozygous.
This indicates that the frequency of NOD2/CARD15
variants is not increased in sepsis patients and NOD2
mutations are not a susceptibility factor for sepsis.
As the Leu1007fsinsC had the most impact in
the mentioned study in stem cell transplantation [36],
we compared three groups: Sepsis patients with WT
NOD2/CARD15, patients carrying the Arg702Trp or
Gly908Arg and individuals with the Leu1007fsinsC
variant. The patient groups did not differ in their baseline
characteristics indicating that NOD2/CARD15 variants
do not provoke early “spontaneous” sepsis (Table 3).
Comorbidity did not seem to play a major role; however,
the pattern of microbiological causes of sepsis (bacteria,
fungi, viruses or idiopathic) was different between the
groups. Gram-positive or Gram-negative bacteria seemed
to play the most prominent role in patients with the
Leu1007fsinsC variant. Only in 50% of the WT patients
bacteria could be grown from blood samples in contrast
to 58% of all individuals with Arg702Trp or Gly908Arg
variants and 100% of Leu1007fsinsC variant patients.
Whereas severity of sepsis as indicated by APACHE
and SAPS scores was not different at admission, there
were significant differences in APACHE score and FiO2
as well as a trend to a higher number of patients with
a pO2/FiO2 ratio < 200 in the Leu1007fsinsC patients in-
dicating functional relevance of NOD2/CARD15 variants
for sepsis outcome. A PaO22/FiO2 ratio below 200 mmHg
is one of the diagnostic criteria of ARDS according to
the American–European Consensus Conference, yet this
ratio is affected by a number of factors such as ventilator
settings and FiO2 per se [51]. The most important finding,
however, was the impact of the Leu1007fsinsC variant
on sepsis-related mortality which was clearly visible
in Kaplan–Meier survival plot and log-rank analysis.
Multivariate analysis further demonstrated Leu1007fsinsC
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Table 3 Baseline characteristics of the patient populations
Parameter WT patients Arg702Trp/Gly908Arg Leu1007fsinsC
Age (years) 55 (range 20–91) 70 (range 17–80) 58 (range 35–93)
Gender (female/male) 33/74 2/15 3/5
Emergency surgery (n) 33 (31) 2 (12) 3 (38)
Malignancy as underlying disease (n) 19 (18) 3 (18) 0
Previous surgery (n) 48 (45) 5 (29) 2 (25)
Gram-positive bacteria found (n) 29 (27) 5 (29) 4 (50)
Gram-negative bacteria found (n) 25 (23) 5 (29) 4 (50)
Fungi, viruses or mixed infections (n) 34 (32) 2 (12) 0
Infectious focus likely to be pulmonary 45 (42) 9 (53) 5 (63)
Infectious focus likely to be intestinal 30 (28) 1 (6) 2 (25)
Pulmonary comorbidity (e.g. COLD, %) 17 41 0
Diabetes (%) 14 0 14
Severe cardiovascular comorbidity (%) 9 0 0
The focus of infection was suggested by the treating physician to be the most likely
Numbers in parentheses are percentages
to be an independent risk factor for early SRM. This is
in line with our finding in stem cells transplantation in
which we also found a major influence of especially the
Leu1007fsinsC variant: Overall, severe GvHD, severe
gastrointestinal GvHD and transplantation related mor-
tality (TRM) at 1 year were significantly increased in
recipient/donor pairs with NOD2/CARD15 mutations as
compared with the WT group [36].
The strong association of TRM with NOD2/CARD15
mutations was partially explained by an increased risk
not only for death from GvHD, but also from respiratory
failure due to diffuse primary or secondary pulmonary
damage. Whereas in the WT group only 11 of 30 (37%)
deaths in remission were caused by GvHD and respiratory
failure, the proportion increased to 17 of 26 (65%) in
pairs with NOD2/CARD15 mutations [36]. In further
analysis by multivariate Cox regression for TRM in the
matched unrelated donor (MUD) cohort (n = 342) the
Leu1007fsinsC variant was the only independent risk
factor identified with a HR of 2.9 (95% CI 1.5–5.5,
p < 0.001) when recipient age, match or mismatch, stage
of underlying disease, use of T-cell depletion and intensity
of conditioning were used as covariates.
As the Leu1007fsinsC mutation has been reported to
impair detection of bacterial translocation and invasion in
the mucosa, our findings may also have implications for
the pathophysiological concept of sepsis: A contribution
of the intestinal barrier to the risk and the disease course
of sepsis has long been discussed. Intestinal permeability
seems to be a factor strongly determining the outcome of
sepsis [52–56]. Bacterial translocation not only occurs in
animal models but also in humans: In patients with fatal
burns more than 50% have intestinal lesions and more than
80% are septic—mostly with intestinal organisms [57].
The association between increased gut permeability and
infectious complications, however, is controversial. So far,
no causative direct link between gut barrier dysfunction
and infectious complications in humans could be identi-
fied. Our study provides the first evidence for a mechanism
that could be involved.
The NOD2/CARD15 protein plays a major role in
the intra-cytoplasmatic response to bacterial cell wall
products and subsequent NF-κB activation in mono-
cytes/macrophages and epithelial cells [58]. The associ-
ation of NOD2/CARD15 mutations with SRM suggests
a predominant role of an impaired monocyte/macrophage
response or an impaired epithelial barrier resulting in
dysregulation of inflammation. The exact mechanisms of
diminished monocyte/macrophage response, impaired bar-
rier function and the imbalance of inflammatory responses
in sepsis remain to be elucidated; however, our findings
indicate that the translocation of intestinal microflora may
directly interfere with immune cell activation and should
stimulate further investigations.
In stem cell transplantation a gut–liver–lung–axis of
impaired elimination of intestinal LPS by the liver has been
postulated to be involved in development of pulmonary
damage [38, 59]. Direct involvement of an impaired mono-
cyte/macrophage response in the lung, however, might
be an alternative explanation and should be addressed in
careful analyses in future studies in SCT as well as in
sepsis.
In conclusion, our data suggest a role of variants
of NOD2/CARD15 gene as a new genetic factor deter-
mining the outcome of sepsis in a subgroup of patients.
As discussed for CD and GvHD, consideration of
sepsis mortality as a result of epithelial barrier and/or
monocyte/macrophage defect resulting in impaired re-
sponse to bacteria could influence the pathophysiological
concepts.
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